Kimble Poon, MD
Cardiovascular Disease · Wailuku, HINPI 1376747410
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 41 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Boston Scientific at 41.3% of the total. Reporting peaked in 2019 at $639 and has fallen 75.8% since, to $154 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in HI, where the typical reported total is $1,979.
Across 41 payments — averaging $38.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$656
- Medtronic$387
- Edwards Lifesciences$277
- Abiomed$91
- Gilead$63
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$38
- plus $76 from 4 others
What the payments were for
- Food & beverage$1,588100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 21 | $656 |
| Medtronic(2 entities) | 7 | $387 |
| Edwards Lifesciences | 2 | $277 |
| Abiomed | 1 | $91 |
| Gilead | 4 | $63 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $38 |
| Abbott | 1 | $24 |
| Medicomp Inc | 1 | $20 |
| Astellas Pharma US Inc | 1 | $16 |
| Penumbra, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,588 in reported general payments places this provider in the 40th percentile of 73 cardiovascular disease providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 12 | $292,310 |
| EliquisApixaban | 63 | $77,824 |
| Repatha SureclickEvolocumab | 78 | $60,969 |
| XareltoRivaroxaban | 51 | $60,431 |
| PradaxaDabigatran Etexilate Mesylate | 171 | $47,229 |
| EntrestoSacubitril/Valsartan | 30 | $44,004 |
| JardianceEmpagliflozin | 50 | $20,013 |
| Repatha PushtronexEvolocumab | 23 | $19,378 |
| Bisoprolol Fumarate | 160 | $3,780 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 19 | $3,687 |
| Metoprolol Succinate | 284 | $3,636 |
| Amiodarone Hcl | 92 | $2,481 |
| Atorvastatin Calcium | 180 | $2,334 |
| Eplerenone | 14 | $2,265 |
| Losartan Potassium | 160 | $1,755 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Wailuku
- Pamela GordonWailuku$3K
- Anil PunjabiWailuku$3K
- Amanda MarnWailuku$2K
- Wazhma AslamyWailuku$2K
- Howard BarbaroshWailuku$2K
- Michael RutledgeWailuku$997
- Jay ParikhWailuku$861
- Dipanjan BanerjeeHonolulu$331K
- Ryan SmithKaneohe$125K
- Ramy BadawiKailua$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.